Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.

BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by the FDA to screen the general population for ovarian cancer. This underscores the critical need for the development of a robust methodology combined with novel technology to detect diagnostic biomarkers for HGSOC in the sera of women. Targeted mass spectrometry (MS) can be used to identify and quantify specific peptides/proteins in complex biological samples with high accuracy, sensitivity, and reproducibility. In this study, we sought to develop and conduct analytical validation of a multiplexed Tier 2 targeted MS parallel reaction monitoring (PRM) assay for the relative quantification of 23 putative ovarian cancer protein biomarkers in sera. METHODS: To develop a PRM method for our target peptides in sera, we followed nationally recognized consensus guidelines for validating fit-for-purpose Tier 2 targeted MS assays. The endogenous target peptide concentrations were calculated using the calibration curves in serum for each target peptide. Receiver operating characteristic (ROC) curves were analyzed to evaluate the diagnostic performance of the biomarker candidates. RESULTS: We describe an effort to develop and analytically validate a multiplexed Tier 2 targeted PRM MS assay to quantify candidate ovarian cancer protein biomarkers in sera. Among the 64 peptides corresponding to 23 proteins in our PRM assay, 24 peptides corresponding to 16 proteins passed the assay validation acceptability criteria. A total of 6 of these peptides from insulin-like growth factor-binding protein 2 (IBP2), sex hormone-binding globulin (SHBG), and TIMP metalloproteinase inhibitor 1 (TIMP1) were quantified in sera from a cohort of 69 patients with early-stage HGSOC, late-stage HGSOC, benign ovarian conditions, and healthy (non-cancer) controls. Confirming the results from previously published studies using orthogonal analytical approaches, IBP2 was identified as a diagnostic biomarker candidate based on its significantly increased abundance in the late-stage HGSOC patient sera compared to the healthy controls and patients with benign ovarian conditions. CONCLUSIONS: A multiplexed targeted PRM MS assay was applied to detect candidate diagnostic biomarkers in HGSOC sera. To evaluate the clinical utility of the IBP2 PRM assay for HGSOC detection, further studies need to be performed using a larger patient cohort.

A dual-binding magnetic immunoassay to predict spontaneous preterm birth.

Complications posed by preterm birth (delivery before 37 weeks of pregnancy) are a leading cause of newborn morbidity and mortality. The previous discovery and validation of an algorithm that includes maternal serum protein biomarkers, sex hormone-binding globulin (SHBG), and insulin-like growth factor-binding protein 4 (IBP4), with clinical factors to predict preterm birth represents an opportunity for the development of a widely accessible point-of-care assay to guide clinical management. Toward this end, we developed SHBG and IBP4 quantification assays for maternal serum using giant magnetoresistive (GMR) sensors and a self-normalizing dual-binding magnetic immunoassay. The assays have a picomolar limit of detections (LOD) with a relatively broad dynamic range that covers the physiological level of the analytes as they change throughout gestation. Measurement of serum from pregnant donors using the GMR assays was highly concordant with those obtained using a clinical mass spectrometry (MS)-based assay for the same protein markers. The MS assay requires capitally intense equipment and highly trained operators with a few days turnaround time, whereas the GMR assays can be performed in minutes on small, inexpensive instruments with minimal personnel training and microfluidic automation. The potential for high sensitivity, accuracy, and speed of the GMR assays, along with low equipment and personnel requirements, make them good candidates for developing point-of-care tests. Rapid turnaround risk assessment for preterm birth would enable patient testing and counseling at the same clinic visit, thereby increasing the timeliness of recommended interventions.

Enhancing water purification through F and Zn-modified Fe-MCM-41 catalytic ozonation.

Due to its low interfacial electron migration ability and highly hydrophilic, Fe-MCM-41 (FeM) had poor activity and stability during catalytic ozonation. To this end, the secondary metal Zn and Si-F group were introduced into the framework of FeM to create surface potential difference and hydrophobic sites. Comparative characterizations showed that there existed rich acid sites with great potential difference on F-Fe-Zn-MCM-41 (FFeZnM). Additionally, because of the existence of hydrophobic and electron-withdrawing Si-F unit, the electron migration ability, hydrophobicity and acidity of FFeZnM were enhanced. The greater O3 mass transfer was induced by Si-F group and O3 was directly activated at Fe and Zn Lewis acid sites into •OH, •O2- and 1O2. With •OH acting as main species, FFeZnM/O3 achieved the superior IBP removal (93.4%, 30 min) and TOC removal (46.6%, 120 min) over those of sole O3 and F-FeM/O3 processes, respectively. HCO3-, Cl-, NO3- and SO42- hindered IBP degradation by FFeZnM/O3, but high concentration humic acid (HA) exhibited promotion by forming HA-IBP complex. IBP degradation by FFeZnM/O3 was enhanced with tap water, river water, and effluent from the secondary sedimentation tank of the sewage plant acting as medium. This study proposed an innovative approach to catalyst design for catalytic ozonation.

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.

Background: Immunotherapy, monotherapy, and immunotherapy plus platinum-based chemotherapy are the standard treatments for advanced non-small cell lung cancer (NSCLC) patients with negative driver genes. However, the impact of similar continuing immunotherapy beyond progression (IBP) of first-line immunotherapy for advanced NSCLC has not yet been shown. This study aimed to estimate the impact of immunotherapy beyond first-line progression (IBF) and evaluate the factors associated with second-line efficacity. Methods: Ninety-four cases of advanced NSCLC patients with progressive disease (PD) post first-line treatment with platinum-based chemotherapy plus immunotherapy and administrated prior immune checkpoint inhibitors (ICIs) between November 2017 and July 2021 were retrospectively analyzed. Survival curves were plotted using the Kaplan-Meier method. Cox proportional hazards regression analyses were applied to determine predictive factors independently associated with second-line efficacity. Results: A total of 94 patients were incorporated in this study. Patients who continued the original ICIs after initial PD were defined as IBF (n=42), whereas those who discontinued immunotherapy were defined as non-IBF (n=52). The second-line objective response rates (ORR, ORR = CR + PR) of patients in the IBF and non-IBF groups were 13.5% vs. 28.6%, respectively (P=0.070). No significant survival difference was found between patients in the IBF and non-IBF groups in first-line median progression-free survival (PFS) (mPFS1, 6.2 vs. 5.1 months, P=0.490), second-line median PFS (mPFS2, 4.5 vs. 2.6 months, P=0.216), or median overall survival (OS) (mOS, 14.4 vs. 8.3 months, P=0.188). However, the benefits inPFS2 were observed in individuals performed PFS1 >6 months (group A) than those of PFS1 ≤6 months (group B) (median PFS2, 4.6 vs. 3.2 months, P=0.038). Multivariate analyses did not reveal any independent prognostic factors for efficacy. Conclusions: The benefits of continuing prior ICIs administration beyond first-line immunotherapy progression might not be obvious in patients with advanced NSCLC, but those first line treatment showed a longer period may receive efficacy benefits.

Adsorption of Ibuprofen as a pharmaceutical pollutant from aqueous phase using zinc oxide nanoparticles: Green synthesis, batch adsorption, and biological activities.

Recent interest has focused on the biosynthesis of metal nanoparticles (NPs), particularly from plants. The production of precipitate served as an early indicator of the presence in the present study's use of ZnO NPs green synthesis of these particles, which was further validated by; Fourier transform infrared spectroscopy, x-ray diffraction. Additionally, the Brunauer-Emmett-Teller was used to calculate the surface area, which came out to be 119.12 m2 /g. Since the true effects of new pollutants, including medicines, on the environment and human health are not well understood, their presence in aquatic systems poses a severe hazard. For this reason, the antibiotic Ibuprofen (IBP) was absorbable to ZnO-NPs in this search. As opposed to fitting to Langmuir isothermally, the adsorption process was discovered to be pseudo-second-order kinetically, and the reaction was determined to be a chemisorption process. The process was endothermic and spontaneous, according to thermodynamic studies. Maximizing IBP removal from aqueous solution required the use of a Box-Behnken surface statistical design with four components, four levels, and response surface modeling. Solution pH, IBP concentration, duration, and dose were the four parameters that were utilized. The regeneration process, which is employed for five cycles with excellent efficiency, is the best benefit of using ZnO-NPs. Examine the elimination of pollutants from actual samples as well. However, the adsorbent is quite effective at reducing biological activity. At high concentrations of ZnO-NPs demonstrated notable antioxidant activity and Red Blood Cell (RBC) hemocompatibility and no discernible hemolysis was seen. ZnO-NPs demonstrated a notable percent suppression of α-amylase up to 53.6% at 400 µg/mL, and so displayed potential as an antidiabetic. Cyclooxygenase was suppressed by ZnO-NPs in an anti-inflammatory test (COX-1 & COX-2) up to 56.32% and 52.04% at a concentration of 400 µg/mL, respectively. Significant anti-Alzheimer potential was demonstrated by ZnO-NPs at 400 µg/mL by inhibiting Acetyl cholinesterase and Butyl cholinesterase up to 68.98 ± 1.62% and 62.36%, respectively. We concluded that guava extract is helpful for ZnO-NP reduction and capping. The bioengineered NPs could prevent Alzheimer's, diabetes, and inflammation and were biocompatible.

The Antimicrobial Peptide AMP-IBP5 Suppresses Dermatitis-like Lesions in a Mouse Model of Atopic Dermatitis through the Low-Density Lipoprotein Receptor-Related Protein-1 Receptor.

The antimicrobial peptide derived from insulin-like growth factor-binding protein 5 (AMP-IBP5) exhibits antimicrobial activities and immunomodulatory functions in keratinocytes and fibroblasts. However, its role in regulating skin barrier function remains unclear. Here, we investigated the effects of AMP-IBP5 on the skin barrier and its role in the pathogenesis of atopic dermatitis (AD). 2,4-Dinitrochlorobenzene was used to induce AD-like skin inflammation. Transepithelial electrical resistance and permeability assays were used to investigate tight junction (TJ) barrier function in normal human epidermal keratinocytes and mice. AMP-IBP5 increased the expression of TJ-related proteins and their distribution along the intercellular borders. AMP-IBP5 also improved TJ barrier function through activation of the atypical protein kinase C and Rac1 pathways. In AD mice, AMP-IBP5 ameliorated dermatitis-like symptoms restored the expression of TJ-related proteins, suppressed the expression of inflammatory and pruritic cytokines, and improved skin barrier function. Interestingly, the ability of AMP-IBP5 to alleviate inflammation and improve skin barrier function in AD mice was abolished in mice treated with an antagonist of the low-density lipoprotein receptor-related protein-1 (LRP1) receptor. Collectively, these findings indicate that AMP-IBP5 may ameliorate AD-like inflammation and enhance skin barrier function through LRP1, suggesting a possible role for AMP-IBP5 in the treatment of AD.

Activation of peroxymonosulfate for degrading ibuprofen via single atom Cu anchored by carbon skeleton and chlorine atom: The radical and non-radical pathways.

Single atomic Cu catalysts (SACs Cu@C) anchored by carbon skeleton and chlorine atom was synthesized by hydrolyzing Cu-MOFs and then pickled by aqua-regia to remove Cu nanoparticles (NPs Cu). Comparative characterizations revealed that SACs Cu@C was a hierarchically porous nanostructure and Cu dispersed uniformly throughout the carbon skeletons. With less active components, SACs Cu@C behaved better in activating PMS over NPs Cu@C on ibuprofen removal (91.3 % versus 30.2 % in 30 min). Two Cu coordination environments were found by EXAF and DFT calculation, including four-coordinated Cu with 4C atoms and six-coordinated Cu with 4Cu and 2Cl atoms. The obvious interfacial electron delivery between PMS and SACs Cu@C was found, which was enhanced by Cl atom. Cu(I)/Cu(II) redox cycle would donate electron to peroxy bond of PMS for generating OH, SO4- and O2-. But electron transferred in opposite direction when PMS bonded to Cu atom through its terminal oxygen atom in sulfate, which formed 1O2. IBP degradation proceeded through both radical and non-radical route. IBP degradation was inhibited with the presence of TBA, methanol and furfuryl alcohol but accelerated by p-BQ, which could accelerate OH generation. Two degradation pathways were deducted. This study provided a new insight into catalysts designed for PMS activation.

Evaluación de la interacción de capecitabina con inhibidores de la bomba de protones en pacientes con cáncer de colon metastásico / Evaluation of the interaction of capecitabin with proton pump inhibitors in patients with metastatic colon cáncer

Objetivo: Evaluar el impacto clínico que la interacción de capecitabina con inhibidores de la bomba de protones (IBP) puede tener sobre la efectividad del tratamiento de mantenimiento en pacientes con cáncer de colon metastásico (CCm). Material y métodos: Estudio retrospectivo, observacional descriptivo que incluyó a todos los pacientes con CCm tratados con capecitabina sola o en combinación entre enero 2013-diciembre 2016. Los pacientes fueron divididos en dos grupos según si fueron o no tratados con IBP concomitantemente con capecitabina. Se evaluaron variables demográficas, farmacológicas y clínicas, siendo la supervivencia libre de progresión (SLP) la variable elegida para evaluar el impacto clínico de la interacción. Resultados: Se incluyeron 150 pacientes. De ellos, el 57,33% varones, media de edad 70,10±12,06 años; el 55,33% tuvieron un ECOG 1 y el 58,67% utilizaron IBP. Un 39,33% fueron tratados con capecitabina en monoterapia, 31,33% CapeOx, y 20% capecitabina+bevacizumab y 9,33% CapeOx+bevacizumab. El 53,33% tuvo un tratamiento basado en capecitabina en primera línea, la frecuencia de variaciones de tratamiento fue de 42,0% reducción de dosis, 38,0% retraso, y 12% interrupción tratamiento. El 78,0% presentó alguna toxicidad, destacando 34,67% diarrea y 30,0% (síndrome mano-pie). La SLP media fue de 6,69 vs 6,0 meses (HR=0,97; IC95% 0,68-1,39; p=0,87) en favor de los pacientes que no utilizaron IBP, aunque la relación fue no significativa. Conclusiones: En la población estudiada, los pacientes con CCm que recibieron tratamiento de mantenimiento basado en capecitabina y que utilizaron IBP simultáneamente, presentaron una tendencia no significativa a la disminución de la SLP. (AU)

Objective: To evaluate the clinical impact that the interaction of capecitabine with proton pump inhibitors (PPIs) may have on the effectiveness of maintenance treatment in patients with metastatic colon cancer (mCC). Material and methods: Retrospective, observational, descriptive study that included all patients with CCm treated with capecitabine alone or in combination between January 2013-December 2016. The patients were divided into two groups according to whether or not they were treated with PPIs concomitantly with capecitabine. Demographic, pharmacological and clinical variables were evaluated, with progression free survival (PFS) being the variable chosen to evaluate the clinical impact of interaction. Results:150 patients were included. Of them, 57.33% were men, mean age 70.10±12.06 years; 55.33% had an ECOG 1 and 58.67% used it in PPIs. 39.33% were treated with capecitabine in monotherapy, 31.33% CapeOx, and 20% capecitabine+bevacizumab and 9.33% CapeOx+bevacizumab. 53.33% had a first-line capecitabine-based treatment, the frequency of treatment variations was 42.0% dose reduction, 38.0% delay, and 12% treatment interruption. 78.0% presented any toxicity, (highlighting 34.67% diarrhea and 30.0% hand-foot syndrome). The mean PFS was 6.69 vs 6.0 months (HR=0.97; 95% CI 0.68-1.39; p=0.87) in favor of patients who did not use IBP, although the relationship was not significant. Conclusions: In the population studied, patients with mCC who received maintenance treatment based on capecitabine and who used PPIs simultaneously, showed a non-significant trend towards a decrease in PFS. (AU)

Effect of perioperative intravenous amiodarone on cardioversion of atrial fibrillation early after video-assisted thoracoscopic surgical ablation: Study protocol for a double-blind randomized controlled trial.

Introduction: Video-assisted thoracoscopic surgical (VATS) ablation is widely performed in surgical areas to treat atrial fibrillation (AF), which is minimally invasive and highly effective. Amiodarone, known as a class III antiarrhythmic agent, has the greatest potential to maintain sinus rhythm of AF. At present, few studies focused on the efficacy of perioperative intravenous amiodarone in the VATS ablation of AF. Therefore, the trial is designed to investigate the effect of perioperative amiodarone infusion on cardioversion of AF early after VATS ablation. Methods: and analysis: This will be a prospective, randomized, double-blind, controlled trial. The trial is to enroll 182 patients aged 18-70 years who will undergo VATS ablation of AF. All eligible participants will be randomly allocated to either the amiodarone or placebo group by using the block randomization in a 1:1 ratio. The primary endpoint will be freedom from atrial arrhythmias 24 h after the VATS procedure and be assessed using the Kaplan-Meier method. All data will be analyzed in accordance with the intention-to-treat principle. Discussion: The clinical trial has been designed to investigate the efficacy of perioperative intravenous amiodarone on cardioversion of AF early after VATS ablation. We are hoping to demonstrate that perioperative infusion of amiodarone could improve the maintenance of sinus rhythm 24 h after VATS ablation.

Effect of antifreeze proteins on the freeze-thaw cycle of foods: fundamentals, mechanisms of action, current challenges and recommendations for future work.

Freezing is widely used in food preservation, but if not carried out properly, ice crystals can multiply (nucleation) or grow (recrystallization) rapidly. This also affects thawing, causing structural damage and affecting overall quality. The objective of this review is to comprehensively study the cryoprotective effect of antifreeze proteins (AFPs), highlighting their role in the freeze-thaw process of food. The properties of AFPs are based on their thermal hysteresis capacity (THC), on the modification of crystal morphology and on the inhibition of ice recrystallization. The mechanism of action of AFPs is based on the adsorption-inhibition theory, but the specific role of hydrogen and hydrophobic bonds/residues and structural characteristics is also detailed. Because of the properties of AFPs, they have been successfully used to preserve the quality of a wide variety of refrigerated and frozen foods. Among the limitations of the use of AFPs, the high cost of production stands out, but currently there are solutions such as the use the production of recombinant proteins, cloning and chemical synthesis. Although in vitro, in vivo and human studies have shown that AFPs are non-toxic, their safety remains a matter of debate. Further studies are recommended to expand knowledge about AFPs, to reduce costs in their large-scale production, to understand their interaction with other food compounds and their possible effects on the consumer.

Axial Pain and Arthritis in Diagnosed Inflammatory Bowel Disease: US National Health and Nutrition Examination Survey Data.

Objective: To estimate the nationally representative prevalence of chronic axial pain, inflammatory back pain (IBP), axial spondyloarthritis (axSpA), and peripheral arthritis in persons diagnosed with inflammatory bowel disease (IBD). Patients and Methods: US National Health and Nutrition Examination Survey (NHANES) data from the 1976-1980 and 2009-2010 survey cycles. Results: In NHANES 1976-1980, the chronic axial pain prevalence in participants with diagnosed ulcerative colitis (UC) was 19.5% vs 7.2% in the general population (P<.01). Neck or upper back, lower back, and Amor criteria-based axial pain were also significantly increased (11.2%, 14.5%, and 13.0%, respectively, vs 3%-5% in the general population (P<.01). In those with diagnosed UC, 40% had axial pain onset at an age older than 45 years; 30.2% reported peripheral arthralgias, and 12.2% reported peripheral arthritis. Arthritis findings on examination were uncommon. In NHANES 2009-2010, axial pain in those diagnosed with IBD had similar patterns. Conclusion: Despite high rates of chronic axial pain in those with IBD, few cases met the IBP and axSpA classification criteria. This apparent discrepancy is unexplained. However, in IBD, axial pain onset at an age older than 45 years is common; and these may not meet IBP and axSpA age criteria. Also, neck pain was increased in those with IBD but is not included in most IBP and axSpA criteria. Peripheral arthralgias and chronic arthritis symptoms were common, but examination findings were not, suggesting that tenosynovitis or enthesitis is more likely than frank arthritis to occur in patients with UC.

Prescripciones de inhibidores de bomba de protones. Análisis de su ajuste a las recomendaciones y evidencias científicas publicadas. / Prescription of proton pump inhibitors. Analysis of their compliance with published recommendations and scientific evidence

JUSTIFICACIÓN: dado elevado consumo de IBP en España, y publicaciones que sugieren una sobreprescripción, es posible revisar desde la farmacia qué medicamentos acompañan al IBP en las recetas, para conocer si su indicación para prevenir gastrolesividad estaría justificada. OBJETIVOS: analizar una muestra de recetas de IBP indicados para prevención de gastrolesividad, averiguando qué porcentaje no se ajustaría a las guías de práctica clínica. MATERIAL Y MÉTODOS: se incluyen en el estudio recetas electrónicas canarias de IBP, de pacientes que retiran su medicación en la farmacia. Se excluyen las recetas de otras Comunidades, recetas en papel y privadas, porque no consta el plan de tratamiento completo. En el acto de dispensación, el paciente firma un consentimiento informado, aunque no se recogen datos de carácter personal. Las variables estudiadas son:- Código Individual del Paciente (CIP), cuyo formato no permite identificarle.- Edad y sexo (extraídos del CIP).- Fecha de la receta.- Fecha de inicio del tratamiento con IBP.- Medicamentos incluidos en la receta. Se descartan los IBP prescritos por primera vez hace menos de tres meses, para descartar posibles tratamientos agudos de patología gástrica. Se considera indicado el IBP para la prevención de gastrolesividad producida por medicamentos cuando se inició hace más de 3 meses. Se elabora un listado de medicamentos gastrolesivos, según las evidencias científicas publicadas. Cuando alguno de ellos aparece en la receta, se considera que el uso de IBP está justificado. RESULTADOS Y DISCUSIÓN: se ha analizado 116 recetas. En 34 (29.3 %) no se halló ningún medicamento gastrolesivo, mientras en 83 (70.7 %) sí se encontraron medicamentos gastrolesivos. De las 67 recetas de mujeres, 17 (25,4 %) no se ajustarían a las evidencias publicadas. (AU)

Prescripciones de inhibidores de bomba de protones. Análisis de su ajuste a las recomendaciones y evidencias científicas publicadas / Proton pump inhibitor prescriptions. Analysis of their compliance with published recommendations and scientific evidence

JUSTIFICACIÓN: dado elevado consumo de IBP en España, y publicaciones que sugieren una sobreprescripción, es posible revisar desde la farmacia qué medicamentos acompañan al IBP en las recetas, para conocer si su indicación para prevenir gastrolesividad estaría justificada.OBJETIVOS: analizar una muestra de recetas de IBP indicados para prevención de gastrolesividad, averiguando qué porcentaje no se ajustaría a las guías de práctica clínica.MATERIAL Y MÉTODOS: se incluyen en el estudio recetas electrónicas canarias de IBP, de pacientes que retiran su medicación en la farmacia. Se excluyen las recetas de otras Comunidades, recetas en papel y privadas, porque no consta el plan de tratamiento completo. En el acto de dispensación, el paciente firma un consentimiento informado, aunque no se recogen datos de carácter personal. Las variables estudiadas son:- Código Individual del Paciente (CIP), cuyo formato no permite identificarle.- Edad y sexo (extraídos del CIP).- Fecha de la receta.- Fecha de inicio del tratamiento con IBP.- Medicamentos incluidos en la receta. Se descartan los IBP prescritos por primera vez hace menos de tres meses, para descartar posibles tratamientos agudos de patología gástrica. Se considera indicado el IBP para la prevención de gastrolesividad producida por medicamentos cuando se inició hace más de 3 meses. Se elabora un listado de medicamentos gastrolesivos, según las evidencias científicas publicadas. Cuando alguno de ellos aparece en la receta, se considera que el uso de IBP está justificado.RESULTADOS Y DISCUSIÓN: se ha analizado 116 recetas. En 34 (29.3 %) no se halló ningún medicamento gastrolesivo, mientras en 83 (70.7 %) sí se encontraron medicamentos gastrolesivos. De las 67 recetas de mujeres, 17 (25,4 %) no se ajustarían a las evidencias publicadas. En hombres, este resultado apareció en 17 recetas de un total de 49 (14, 3%). No se halló diferencia significativa entre sexos (Χ2 = 0,01, p =0,05). (AU)

Correcto uso de fármacos inhibidores de la bomba de protones frente a fármacos antiácidos / Correct use of proton pump inhibitors vs. antacid drugs

JUSTIFICACIÓN: en este estudio se promueve el correcto uso, desde la farmacia comunitaria, de los llamados agentes contra la úlcera péptica y el reflujo gastroesofágico, al que pertenecen entre otros los inhibidores de la bomba de protones (IBP) (omeprazol, lansoprazol, rabeprazol, pantoprazol, y esomeprazol) frente a los antiácidos no sistémicos, como las sales de aluminio y magnesio. El primer grupo se indica para tratar afecciones que cursan con una elevada e inusual secreción de ácido clorhídrico, de todos, los IBP son los fármacos de mayor consumo, en concreto el omeprazol, según un informe publicado en 2021 por la Agencia Española del Medicamento. Del mismo modo, se debe prestar atención a la dispensación de antiácidos, y en qué ocasiones es adecuado utilizarlos frente al grupo anterior. Los antiácidos están indicados para el alivio de los síntomas de acidez y ardor de estómago de forma puntual, sin embargo, si se usan con demasiada frecuencia para tratar síntomas recurrentes, sin consultar al médico, podría enmascararse alguna patología de riesgo, o causar efecto rebote.OBJETIVOS: el principal objetivo de este trabajo es promover el uso adecuado de los IBP desde la Farmacia Comunitaria, frente a los antiácidos no sistémicos.MATERIALES Y METODOS: para el presente trabajo se ha realizado una revisión bibliográfica de fármacos antiulcerosos y antiácidos, sus indicaciones y efectos adversos. (AU)

Bias Associated with Peripheral Non-Invasive Compared to Invasive Arterial Blood Pressure Monitoring in Healthy Anaesthetised and Standing Horses Using the Bionet BM7Vet.

To compare arterial blood pressure (ABP) measured invasively (IBP) to ABP measured non-invasively (NIBP) via oscillometry in healthy anaesthetised and standing horses using the Bionet BM7Vet. Fourteen horses were anaesthetised for elective procedures (anaesthetised group) and 10 horses were enrolled for standing blood pressure manipulation (standing group). In both groups, IBP and NIBP-corrected to heart level were measured every 3 min using the Bionet BM7Vet. The overall mean difference (bias), standard deviation and limits of agreement (LOA) were calculated for paired IBP and NIBP systolic (SAP), mean (MAP) and diastolic (DAP) blood pressure measurements. In anaesthetised horses, the NIBP cuff was placed at either the proximal tail base or the metacarpus. Invasive MAP was used to retrospectively characterise measurements into hypotensive (≤70 mm Hg), normotensive (71-110 mm Hg) or hypertensive (≥111 mm Hg) subgroups. In standing horses, the NIBP cuff was placed at the tail base only and invasive MAP was manipulated to achieve hypertension (≥126 mm Hg) and hypotension (≤90 mm Hg) using phenylephrine and acepromazine, respectively. When measuring NIBP at the tail in anaesthetised horses, the Bionet BM7Vet failed on 8/185 occasions and overestimated SAP, MAP and DAP during hypotension and normotension. The biases (lower, upper LOA) for MAP were -11.4 (-33.3, 10.5) and -6.0 (-25.8, 13.8) mm Hg, respectively. Hypertension could not be evaluated. When measuring NIBP at the metacarpus in anaesthetised horses, the Bionet BM7Vet failed on 24/65 occasions and underestimated SAP, MAP and DAP when all ABP subgroups were combined. The bias (lower, upper LOA) for pooled MAP was 3.6 (-44.3, 51.6) mm Hg. When measuring NIBP at the tail in standing horses, the Bionet BM7Vet failed on 64/268 occasions and underestimated SAP, MAP and DAP during hypotension, normotension and hypertension. The biases (lower, upper LOA) for MAP were 16.3 (-10.5, 43.1), 16.6 (-19.5, 52.7) and 30.0 (-8.1, 68.0) mm Hg, respectively. Monitoring NIBP on the Bionet BM7Vet in anaesthetised horses overestimated ABP at the tail and underestimated ABP at the metacarpus. The device inaccurately detected hypotension and should be used cautiously. In standing horses, the Bionet BM7Vet underestimated ABP at the tail, especially during pharmacologically induced hypertension.

[Degradation Characteristics and Mechanism of Ibuprofen by Ozone Catalyzed by Nitrogen-Doped Biochar].

This study used a novel nitrogen-doped biochar (N-C) to catalyze the oxidative degradation of IBP in water by ozone and studied the catalytic ozone oxidation degradation of ibuprofen (IBP) efficiency and mechanism. Furthermore, it explored the influence of pH, ozone dosing quantity, catalyst dosing quantity, different anions, and background of water quality conditions on the IBP degradation efficiency. The results showed that, compared with that of some common carbon-based catalysts (g-C3N4, biochar, and granular-activated carbon) and metal catalysts (MnO2 and Fe3O4), the N-C catalytic ozone system had a very outstanding oxidation degradation performance of organic pollutants; the removal rate of IBP reached 100% in 5 min, and the utilization rate of ozone was increased from 10% to 46%. The treatment efficiency of the system was enhanced with the increase in pH. Compared with that by increasing the ozone dosage, the treatment capacity of the system was significantly improved by increasing the concentration of catalyst. The quenching experiment and EPR further confirmed that N-C could effectively catalyze ozone to produce more reactive oxygen species, such as superoxide radicals (·O2-) and H2O2. It was also found that·O2- was the main active substance in the reaction system and played a leading role in the degradation of IBP.

Performance of a validated spontaneous preterm delivery predictor in South Asian and Sub-Saharan African women: a nested case control study.

OBJECTIVES: To address the disproportionate burden of preterm birth (PTB) in low- and middle-income countries, this study aimed to (1) verify the performance of the United States-validated spontaneous PTB (sPTB) predictor, comprised of the IBP4/SHBG protein ratio, in subjects from Bangladesh, Pakistan and Tanzania enrolled in the Alliance for Maternal and Newborn Health Improvement (AMANHI) biorepository study, and (2) discover biomarkers that improve performance of IBP4/SHBG in the AMANHI cohort. STUDY DESIGN: The performance of the IBP4/SHBG biomarker was first evaluated in a nested case control validation study, then utilized in a follow-on discovery study performed on the same samples. Levels of serum proteins were measured by targeted mass spectrometry. Differences between the AMANHI and U.S. cohorts were adjusted using body mass index (BMI) and gestational age (GA) at blood draw as covariates. Prediction of sPTB < 37 weeks and < 34 weeks was assessed by area under the receiver operator curve (AUC). In the discovery phase, an artificial intelligence method selected additional protein biomarkers complementary to IBP4/SHBG in the AMANHI cohort. RESULTS: The IBP4/SHBG biomarker significantly predicted sPTB < 37 weeks (n = 88 vs. 171 terms ≥ 37 weeks) after adjusting for BMI and GA at blood draw (AUC= 0.64, 95% CI: 0.57-0.71, p < .001). Performance was similar for sPTB < 34 weeks (n = 17 vs. 184 ≥ 34 weeks): AUC = 0.66, 95% CI: 0.51-0.82, p = .012. The discovery phase of the study showed that the addition of endoglin, prolactin, and tetranectin to the above model resulted in the prediction of sPTB < 37 with an AUC= 0.72 (95% CI: 0.66-0.79, p-value < .001) and prediction of sPTB < 34 with an AUC of 0.78 (95% CI: 0.67-0.90, p < .001). CONCLUSION: A protein biomarker pair developed in the U.S. may have broader application in diverse non-U.S. populations.

Clinical Validation of a Proteomic Biomarker Threshold for Increased Risk of Spontaneous Preterm Birth and Associated Clinical Outcomes: A Replication Study.

Preterm births are the leading cause of neonatal death in the United States. Previously, a spontaneous preterm birth (sPTB) predictor based on the ratio of two proteins, IBP4/SHBG, was validated as a predictor of sPTB in the Proteomic Assessment of Preterm Risk (PAPR) study. In particular, a proteomic biomarker threshold of -1.37, corresponding to a ~two-fold increase or ~15% risk of sPTB, significantly stratified earlier deliveries. Guidelines for molecular tests advise replication in a second independent study. Here we tested whether the significant association between proteomic biomarker scores above the threshold and sPTB, and associated adverse outcomes, was replicated in a second independent study, the Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP). The threshold significantly stratified subjects in PAPR and TREETOP for sPTB (p = 0.041, p = 0.041, respectively). Application of the threshold in a Kaplan-Meier analysis demonstrated significant stratification in each study, respectively, for gestational age at birth (p < 001, p = 0.0016) and rate of hospital discharge for both neonate (p < 0.001, p = 0.005) and mother (p < 0.001, p < 0.001). Above the threshold, severe neonatal morbidity/mortality and mortality alone were 2.2 (p = 0.0083,) and 7.4-fold higher (p = 0.018), respectively, in both studies combined. Thus, higher predictor scores were associated with multiple adverse pregnancy outcomes.

Removal of Ibuprofen at Low Concentration Using a Newly Formulated Emulsion Liquid Membrane.

Ibuprofen (IBP) is a pharmaceutical product that is widely prescribed as an over-the-counter painkiller. It has been classified as a contaminant of emerging concern (CEC) that has received global attention in the search for a better wastewater separation technology. The emulsion liquid membrane (ELM) is one of the potential solutions for IBP removal from wastewater owing to its advantages, such as the ability to remove a highly soluble solute, energy efficient and tuneable formulation. To develop this ELM, a series of parameters such as stirring speed, emulsification time, organic to internal phase volume ratio (O/I), internal phase concentration, carrier concentration and surfactant concentration were studied. The extraction was carried out for 15 min stirring time and the concentration of IBP in the feed phase was determined using a UV-Vis spectrophotometer. The optimum formulation for the ELM was found at 300 rpm stirring speed, 20 min emulsification time, 3:1 of O/I, 0.1 M ammonia, NH3 (stripping agent), 6 wt% trioctylamine, TOA (carrier) and 2 wt% sorbitan monooleate, Span 80 (non-ionic surfactant). IBP removal of 89% was achieved at the optimum parameters of ELM. The current research demonstrated that a newly formulated ELM has great potential in removing a low concentration IBP from wastewater.